# Forensic Dossier: Study Forensics: APJ agonist as pharmacological exercise mimetic

**Run ID:** `full27_study-forensics-030_Claude_Haiku_dbb9b0`  
**Task:** study-forensics-030 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T18:02:28.901926+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** preclinical_to_therapeutic_leap  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **71.8/100** (margin: 0.0)
**Failure modes:** unsupported_intermediate_step
**Forensic flags:** 3
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 3.9/6 | 5.5/6 | 5.6/8 | 8.0/8 | 0.0/10 | 8.5/10 | **71.8/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [+] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** cautious_scope_control, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "mechanism_vs_evidence"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 1.2/8
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "6. CLASSIFICATION DECISION: The primary problem is the evidence-tier mismatch (animal → human therapeutic claim), not rh"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "The text implies clinical translation ('preparing to translate into human trials') as a reasonable next step."
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[1]`: "Whether the apelin/APJ pathway has prior human validation (e.g., from genetic studies or biomarker work) that would stre"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 5.5/6
  - (+) `alternative_hypotheses[1]`: "OVERCLAIM: If the text had used language like 'the drug reduces HbA1c in patients' or 'this approach transforms diabetes"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 2/3 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[3]`: "Is this overclaim or mechanism_vs_evidence? Mechanism_vs_evidence. The text does not aggressively sell the drug as effec"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.71, 632 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength, structural_reasoning_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/10 content words)
  - `key_claims[0]`: "The drug improved glycemic control and HbA1c in obese/diabetic mice — ANIMAL EVIDENCE, not human."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/14 content words)
  - `key_claims[1]`: "Combined with incretin therapy, it nearly doubled weight loss and preserved muscle mass — ANIMAL EVI"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/10 content words)
  - `key_claims[2]`: "It reduced cardiac hypertrophy and injury markers in a heart-failure model — ANIMAL EVIDENCE, not hu"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "The company claims it 'could serve as a pharmacological exercise mimetic' — HUMAN THERAPEUTIC IMPLIC"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/10 content words)
  - `key_claims[4]`: "The company is 'preparing to translate into human trials' — FUTURE INTENT, not current evidence."
- **[WARN]** `[HEURISTIC]` `claim_step_alignment`: Key claim 2 not well supported in reasoning steps (2/14 content words found)
  - `key_claims[1]`: "Combined with incretin therapy, it nearly doubled weight loss and preserved muscle mass — ANIMAL EVI"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "SOLID: If the text had reported human pilot data (even small-scale) showing safety and biomarker imp"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14977ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.88

**Assumptions:**
- The study involved mouse models of obesity, diabetes, and heart failure (not human subjects).
- The company is making claims about human therapeutic potential based on animal efficacy.
- The text implies clinical translation ('preparing to translate into human trials') as a reasonable next step.
- No human safety, pharmacokinetics, or efficacy data are mentioned.
- The phrase 'exercise mimetic' is aspirational language that frames the mechanism in human terms.

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: All results are from preclinical mouse models (obese/diabetic mice, heart-failure model). This is animal-model evidence (tier 2).
2. 2. CONCLUSION TIER IDENTIFICATION: The company claims the drug 'could serve as a pharmacological exercise mimetic' and is preparing human trials. This implies human therapeutic benefit (tier 5: clinical human).
3. 3. BRIDGE GAP: There is a 3-tier gap between animal models and human therapeutic claims. No human data, pilot studies, or biomarker validation in humans is mentioned.
4. 4. HEDGE ANALYSIS: The text uses cautious framing ('could serve as,' 'preparing to translate') but these hedges acknowledge the gap without closing it. They do not constitute evidence that the drug will work in humans.
5. 5. RHETORICAL TONE: The language is analytical rather than promotional ('reported preclinical results,' 'improved,' 'reduced'). There is no use of 'breakthrough,' 'confirms,' or 'transforms.' The tone is measured.
6. 6. CLASSIFICATION DECISION: The primary problem is the evidence-tier mismatch (animal → human therapeutic claim), not rhetorical inflation. The text stays within cautious language but still implies human benefit from animal-only data. This is mechanism_vs_evidence.

**Key Claims:**
- The drug improved glycemic control and HbA1c in obese/diabetic mice — ANIMAL EVIDENCE, not human.
- Combined with incretin therapy, it nearly doubled weight loss and preserved muscle mass — ANIMAL EVIDENCE, not human.
- It reduced cardiac hypertrophy and injury markers in a heart-failure model — ANIMAL EVIDENCE, not human.
- The company claims it 'could serve as a pharmacological exercise mimetic' — HUMAN THERAPEUTIC IMPLICATION, not supported by human data.
- The company is 'preparing to translate into human trials' — FUTURE INTENT, not current evidence.

**Alternative Hypotheses:**
- SOLID: If the text had reported human pilot data (even small-scale) showing safety and biomarker improvement, the conclusion tier would match the evidence tier, and the analysis would be solid.
- OVERCLAIM: If the text had used language like 'the drug reduces HbA1c in patients' or 'this approach transforms diabetes treatment,' the primary problem would be false or unsupported claims, not tier mismatch. That would be overclaim.
- CORRELATION_VS_CAUSATION: Not applicable here. The mouse studies appear to be mechanistic (drug given, outcomes measured), not observational.

**Uncertainties:**
- Whether the company has unpublished human safety data or preliminary human studies not mentioned in this summary.
- Whether the apelin/APJ pathway has prior human validation (e.g., from genetic studies or biomarker work) that would strengthen the bridge. The summary does not mention this.
- Whether 'preparing to translate into human trials' means IND-enabling studies are underway or if this is purely aspirational.
- The quality and rigor of the mouse studies themselves (e.g., sample size, blinding, statistical power). The summary does not provide methodological detail.

**Self-Verification:**
- Did I overstate the problem? No. The evidence is clearly animal-only, and the conclusion is clearly human-directed. This is a genuine tier mismatch.
- Did I miss a solid aspect? No. The study design appears sound for preclinical work, but preclinical work cannot support human therapeutic claims without a bridge.
- Did I confuse hedging with evidence? Yes, initially — but I corrected it. Hedges like 'could' and 'preparing to' acknowledge uncertainty but do not provide human evidence.
- Is this overclaim or mechanism_vs_evidence? Mechanism_vs_evidence. The text does not aggressively sell the drug as effective in humans; it reports animal results and notes that human trials are planned. The problem is the tier gap, not rhetorical inflation.
- Did I apply the PRIORITY RULE correctly? Yes. The text is analytical, not promotional. The main forensic finding is the evidence-tier mismatch, not inflated claims.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.5/6 `#########.`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **71.8/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.5/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 15.0s | 71.8/100 | 4.8 |

Failure modes observed: unsupported_intermediate_step.
